



47

PATIENTS RECRUITED

Issue no.2, November 2022

NEWS

Welcome to our second issue of the CHIP-BCIS3 newsletter! We've recruited a total of 47 patients and we thank all the teams for their continued effort to identify, screen and enrol patients into the study.

Since our last newsletter, we've recruited 7 patients which is steady progress towards our goal of 250 patients. Recruiting centres have included the teams at Bart's, Bournemouth, St Thomas' and King's College. Great work!

We'd love to end the year with a strong finish and we'll be sending the following prizes to sites which recruit patients before the end of the year. Local targets will be communicated shortly to each site by email.

- 1 patient - Box of chocolates
- 2 patients - Small hamper
- 3 patients - Medium hamper



SITE UPDATE

There are now ten sites open to recruitment in CHIP-BCIS3, with a big welcome to **Glenfield Hospital, Leicester**. Thanks to all sites for their ongoing effort!

We're working hard towards bringing more sites onboard over the coming months.



NEW STAFF

We want to welcome Matt Kwok as the new CHIP-BCIS3 trial manager, who is taking over the reins from Addi Perkins.



Hi! I originally moved to London from Sydney about 7 years ago (where did this time go?!).

I previously worked at King's College London in food allergy research and have recently joined the CTU team in helping to continue to deliver important and exciting cardiovascular trials. It's been a steep learning curve and I very much look forward to working with everyone at an important stage of the CHIP-BCIS3 trial.

Outside of work, I enjoy long distance running and cycling.

RECAP FROM THE INVESTIGATORS' MEETING



The Investigators' Meeting was held at King's College London, Strand Campus on Friday 7th October with a great turn-out and interesting talks from many of our collaborators. Thank you to all who attended and contributed to the day, both in-person and remotely.

We've condensed the meeting into a few key messages below:

- There is no strong evidence for pLVAD unloading in high risk PCI – remind people that they do not already know the result of this trial.
- Bring in TAVI operators to support with large bore access.
- If you are based at a centre that has an impella program and routinely uses pLVAD, this trial will save the trust money. The cost of the device is going to increase in Spring next year, which may put some impella programs at risk. The best way to protect those is by enrolling into CHIP-BCIS3.
- Patient and Public Involvement (PPI) isn't participation in research (they are still often conflated!) - it's doing research with people, not for them.
- The outcomes in cardiology trials should align with what's important to the people living with heart disease, not just those perceived by researchers and clinicians.
- We spent time trying to ensure the CHIP-BCIS3 Patient Information Sheet (PIS) told potential participants what they wanted to know, in an accessible way.

CONTACT



If you have any questions, please don't hesitate to contact the CTU team - Matt Kwok, Megan Knight, Laura Van Dyck and Richard Evans.

Email: CHIP-BCIS3@LSHTM.ac.uk

Tel: +44 (0)20 7927 2723

Twitter: [@CHIP_BCIS3](https://twitter.com/CHIP_BCIS3)



NHS

Guy's and St Thomas'
NHS Foundation Trust

KING'S
College
LONDON

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE

